Analysts Predict 11% Growth for FVD in the Future
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The First Trust Value Line Dividend Index Fund ETF (FVD) has an implied analyst target price of $51.46 per unit, indicating an 11.27% upside from its recent trading price of $46.25.
Notable Holdings: Key underlying holdings with significant upside potential include Takeda Pharmaceutical Co Ltd (28.46% upside), Diageo plc (14.62% upside), and BCE Inc (14.37% upside) based on their respective analyst target prices.
Market Sentiment: The disparity between current trading prices and analyst target prices raises questions about whether analysts are justified in their optimism or if they are lagging behind recent developments in the companies and industries.
Investor Considerations: Investors are encouraged to conduct further research to assess the validity of analyst targets, as high price targets may indicate optimism but could also lead to downgrades if they are based on outdated information.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.910
Low
18.00
Averages
18.00
High
18.00
Current: 15.910
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
- Clinical Trial Success: Takeda's tyrosine kinase inhibitor, zasocitinib, significantly outperformed the rival therapy Sotyktu in the LATITUDE trial, with over 35% of patients achieving complete skin clearance, more than 2.5 times higher than Sotyktu, indicating its strong therapeutic potential.
- Safety Profile: The trial reported no new safety concerns, and zasocitinib was well tolerated, consistent with prior studies, which supports its future marketability and acceptance among healthcare providers.
- Market Application Plans: Takeda intends to submit marketing applications for zasocitinib to the U.S. FDA and other regulatory agencies within this fiscal year, aiming to capitalize on its promising results in psoriasis treatment.
- Future Data Presentation: The company plans to present full LATITUDE trial data at an upcoming medical event, which will provide deeper insights for investors and the medical community, thereby enhancing market confidence.
See More
Zasocitinib Shows Superiority in Psoriasis Study
- Clinical Trial Results: In a Phase 3 trial for moderate-to-severe plaque psoriasis, zasocitinib (TAK-279) achieved over 35% complete skin clearance (PASI 100) at week 16, which is 2.5 times the response rate of deucravacitinib, demonstrating significant efficacy superiority.
- Safety Profile: The safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified, indicating good tolerability for long-term use and providing a safer treatment option for patients.
- Future Development Plans: Takeda plans to present detailed data at upcoming medical congresses and expects to submit a New Drug Application to the FDA for plaque psoriasis this fiscal year, further advancing zasocitinib's market entry.
- Market Potential: As a next-generation TYK2 inhibitor with over 1 million-fold selectivity, zasocitinib has the potential to become the preferred oral treatment option for psoriasis patients, addressing the growing market demand.
See More
Takeda's ENTYVIO Receives FDA Acceptance for Pediatric Use
- FDA Application Acceptance: Takeda's supplemental Biologics License Application for ENTYVIO (vedolizumab) targeting moderately to severely active ulcerative colitis and Crohn's disease in pediatric patients aged 2 and older has been accepted by the FDA, with a PDUFA date expected in Q1 2027, indicating the company's strategic focus on pediatric IBD treatment.
- Market Expansion Plans: In addition to the U.S., Takeda has submitted a marketing authorization application for ENTYVIO IV to the European Medicines Agency and plans to submit applications in additional markets later this year, demonstrating the company's commitment to global market expansion and enhancing its competitiveness in the biopharmaceutical sector.
- Clinical Trial Support: The application is supported by data from two randomized, double-blind, multicenter Phase 3 trials in patients aged 2 to 17, namely the KEPLER study for UC and the ongoing WEBB study for Crohn's disease, showcasing ENTYVIO's efficacy and safety in pediatric patients and bolstering market acceptance.
- Financial Performance: For the fiscal year ending March 31, 2026, global revenue for ENTYVIO increased by 4.8% to 958 billion yen, reflecting sustained demand for the product and the company's robust performance in the IBD treatment market.
See More
Takeda Seeks FDA Approval for ENTYVIO in Pediatric Patients
- FDA Review Progress: Takeda announced that its supplemental Biologics License Application for ENTYVIO (vedolizumab) targeting pediatric patients aged 2 and older has been accepted for review by the FDA, and if approved, it will be the only gut-focused treatment option for these patients, demonstrating the company's commitment to addressing unmet treatment needs.
- Urgent Treatment Needs: The prevalence of inflammatory bowel disease (IBD) continues to rise among children and adolescents, with approximately 25% diagnosed before age 20, and the approval of ENTYVIO would provide new treatment options for this challenging patient population, aiding in achieving clinical remission.
- Clinical Trial Support: The application is supported by data from two randomized, double-blind Phase 3 trials focused on UC and Crohn's disease, demonstrating the efficacy and safety of ENTYVIO in pediatric patients, further solidifying its successful track record in adult treatment.
- Global Market Expansion: In addition to the U.S., Takeda has submitted a marketing authorization application for ENTYVIO to the European Medicines Agency and plans to submit applications in additional markets in the coming months, reflecting its strategic commitment to advancing pediatric IBD treatment globally.
See More
Takeda Pharmaceutical Shares Enter Oversold Territory
- Oversold Signal: Takeda Pharmaceutical (TAK) shares hit an RSI of 25.9 on Friday, indicating an oversold condition as the stock traded as low as $16.07 per share, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek entry points.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 72.1, TAK's low RSI could attract bullish investors, indicating potential for a market sentiment reversal and paving the way for future price rebounds.
- Historical Performance Analysis: TAK's 52-week low is $12.99 and high is $18.895, with the last trade at $16.25, demonstrating relative stability within its trading range, which may appeal to value-seeking buyers.
- Investor Sentiment: Despite the current oversold status, investors should carefully assess market sentiment and technical indicators to avoid making impulsive decisions in an uncertain market environment.
See More
Innovent's IBI363 Shows Survival Benefits in Lung Cancer Treatment
- Clinical Data Update: At the 2026 ASCO Annual Meeting, Innovent presented updated clinical data for its PD-1/IL-2α bispecific fusion protein IBI363, demonstrating a favorable long-term safety profile in immunotherapy-resistant non-small cell lung cancer (NSCLC), reinforcing its competitive edge in this area.
- Significant Survival Improvement: Among 67 squamous NSCLC patients without known EGFR mutations, the 3 mg/kg Q3W dose group achieved a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months, with a 24-month OS rate of 47.8%, highlighting IBI363's substantial survival advantage.
- Impact of Smoking History: In 58 EGFR wild-type adenocarcinoma patients, those with a smoking history had a median OS of 23.4 months, indicating that smoking history may significantly influence the efficacy of IBI363 in immunotherapy-resistant adenocarcinoma, further emphasizing its clinical potential.
- Favorable Safety Profile: In a long-term follow-up of 136 patients, IBI363 exhibited a treatment-emergent adverse event rate of 48.5%, primarily manageable arthralgia and anemia, with no new safety signals observed, indicating its viability for clinical use.
See More
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
- Clinical Trial Success: Takeda's tyrosine kinase inhibitor, zasocitinib, significantly outperformed the rival therapy Sotyktu in the LATITUDE trial, with over 35% of patients achieving complete skin clearance, more than 2.5 times higher than Sotyktu, indicating its strong therapeutic potential.
- Safety Profile: The trial reported no new safety concerns, and zasocitinib was well tolerated, consistent with prior studies, which supports its future marketability and acceptance among healthcare providers.
- Market Application Plans: Takeda intends to submit marketing applications for zasocitinib to the U.S. FDA and other regulatory agencies within this fiscal year, aiming to capitalize on its promising results in psoriasis treatment.
- Future Data Presentation: The company plans to present full LATITUDE trial data at an upcoming medical event, which will provide deeper insights for investors and the medical community, thereby enhancing market confidence.
See More
Zasocitinib Shows Superiority in Psoriasis Study
- Clinical Trial Results: In a Phase 3 trial for moderate-to-severe plaque psoriasis, zasocitinib (TAK-279) achieved over 35% complete skin clearance (PASI 100) at week 16, which is 2.5 times the response rate of deucravacitinib, demonstrating significant efficacy superiority.
- Safety Profile: The safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified, indicating good tolerability for long-term use and providing a safer treatment option for patients.
- Future Development Plans: Takeda plans to present detailed data at upcoming medical congresses and expects to submit a New Drug Application to the FDA for plaque psoriasis this fiscal year, further advancing zasocitinib's market entry.
- Market Potential: As a next-generation TYK2 inhibitor with over 1 million-fold selectivity, zasocitinib has the potential to become the preferred oral treatment option for psoriasis patients, addressing the growing market demand.
See More
Takeda's ENTYVIO Receives FDA Acceptance for Pediatric Use
- FDA Application Acceptance: Takeda's supplemental Biologics License Application for ENTYVIO (vedolizumab) targeting moderately to severely active ulcerative colitis and Crohn's disease in pediatric patients aged 2 and older has been accepted by the FDA, with a PDUFA date expected in Q1 2027, indicating the company's strategic focus on pediatric IBD treatment.
- Market Expansion Plans: In addition to the U.S., Takeda has submitted a marketing authorization application for ENTYVIO IV to the European Medicines Agency and plans to submit applications in additional markets later this year, demonstrating the company's commitment to global market expansion and enhancing its competitiveness in the biopharmaceutical sector.
- Clinical Trial Support: The application is supported by data from two randomized, double-blind, multicenter Phase 3 trials in patients aged 2 to 17, namely the KEPLER study for UC and the ongoing WEBB study for Crohn's disease, showcasing ENTYVIO's efficacy and safety in pediatric patients and bolstering market acceptance.
- Financial Performance: For the fiscal year ending March 31, 2026, global revenue for ENTYVIO increased by 4.8% to 958 billion yen, reflecting sustained demand for the product and the company's robust performance in the IBD treatment market.
See More
Takeda Seeks FDA Approval for ENTYVIO in Pediatric Patients
- FDA Review Progress: Takeda announced that its supplemental Biologics License Application for ENTYVIO (vedolizumab) targeting pediatric patients aged 2 and older has been accepted for review by the FDA, and if approved, it will be the only gut-focused treatment option for these patients, demonstrating the company's commitment to addressing unmet treatment needs.
- Urgent Treatment Needs: The prevalence of inflammatory bowel disease (IBD) continues to rise among children and adolescents, with approximately 25% diagnosed before age 20, and the approval of ENTYVIO would provide new treatment options for this challenging patient population, aiding in achieving clinical remission.
- Clinical Trial Support: The application is supported by data from two randomized, double-blind Phase 3 trials focused on UC and Crohn's disease, demonstrating the efficacy and safety of ENTYVIO in pediatric patients, further solidifying its successful track record in adult treatment.
- Global Market Expansion: In addition to the U.S., Takeda has submitted a marketing authorization application for ENTYVIO to the European Medicines Agency and plans to submit applications in additional markets in the coming months, reflecting its strategic commitment to advancing pediatric IBD treatment globally.
See More
Takeda Pharmaceutical Shares Enter Oversold Territory
- Oversold Signal: Takeda Pharmaceutical (TAK) shares hit an RSI of 25.9 on Friday, indicating an oversold condition as the stock traded as low as $16.07 per share, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek entry points.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 72.1, TAK's low RSI could attract bullish investors, indicating potential for a market sentiment reversal and paving the way for future price rebounds.
- Historical Performance Analysis: TAK's 52-week low is $12.99 and high is $18.895, with the last trade at $16.25, demonstrating relative stability within its trading range, which may appeal to value-seeking buyers.
- Investor Sentiment: Despite the current oversold status, investors should carefully assess market sentiment and technical indicators to avoid making impulsive decisions in an uncertain market environment.
See More
Innovent's IBI363 Shows Survival Benefits in Lung Cancer Treatment
- Clinical Data Update: At the 2026 ASCO Annual Meeting, Innovent presented updated clinical data for its PD-1/IL-2α bispecific fusion protein IBI363, demonstrating a favorable long-term safety profile in immunotherapy-resistant non-small cell lung cancer (NSCLC), reinforcing its competitive edge in this area.
- Significant Survival Improvement: Among 67 squamous NSCLC patients without known EGFR mutations, the 3 mg/kg Q3W dose group achieved a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months, with a 24-month OS rate of 47.8%, highlighting IBI363's substantial survival advantage.
- Impact of Smoking History: In 58 EGFR wild-type adenocarcinoma patients, those with a smoking history had a median OS of 23.4 months, indicating that smoking history may significantly influence the efficacy of IBI363 in immunotherapy-resistant adenocarcinoma, further emphasizing its clinical potential.
- Favorable Safety Profile: In a long-term follow-up of 136 patients, IBI363 exhibited a treatment-emergent adverse event rate of 48.5%, primarily manageable arthralgia and anemia, with no new safety signals observed, indicating its viability for clinical use.
See More
